Panome Bio at AACR 2025: Launching Global Phosphoproteomics and Advancing Cancer Discovery
Panome Bio returned to the AACR Annual Meeting in Chicago this April for our third consecutive year as an exhibitor, marking a milestone moment with the launch of our new global phosphoproteomics service. As one of the most influential conferences in cancer research, AACR 2025 was the ideal platform to introduce this powerful service to the oncology community—and to connect with researchers driving the next wave of multi-omic innovation.
New Service Launch: Global Phosphoproteomics
Just ahead of the meeting, Panome Bio unveiled our global phosphoproteomics service, providing researchers with unmatched coverage of phosphorylation events using our next-generation mass spectrometry platform. This new capability offers comprehensive profiling of phosphorylation states across thousands of proteins—enabling a deeper understanding of cellular signaling in cancer biology, treatment response, and resistance mechanisms.
At our booth, attendees explored how this new service integrates seamlessly with Panome’s existing metabolomics and proteomics platforms, creating an end-to-end solution for truly integrated, multi-omic discovery.
Engaging with the Community
Monday, April 28
We were thrilled to host Dr. Gary Patti, Panome Bio’s Chief Scientific Officer, at our exhibit booth. Dr. Patti engaged with researchers throughout the day, discussing the future of multi-omic analysis and how Panome Bio is helping redefine what’s possible in systems-level cancer research.
Scientific Contributions at AACR 2025
Tuesday, April 29
Poster Presentation
Unbiased Phosphoproteomic and Metabolic Profiling in WT and KRAS Mutant Colorectal Cancer Cells
Presenter: Dr. Ethan Stancliffe, Senior Director of R&D, Panome Bio This poster showcased how Panome’s integrated platform reveals novel insights into oncogenic signaling by combining untargeted metabolomics with global phosphoproteomics—highlighting the value of multi-layered data in characterizing KRAS-driven cancers.
Partner Presentation
Integrated Multi-Omics Unlocks Holistic Phenotypic Insights Allowing for Deep Molecular Exploration
Presenter: Dr. Andrea O’Hara, GENEWIZ from Azenta Life Sciences This presentation, delivered in collaboration with Azenta Life Sciences, demonstrated how researchers are leveraging Panome Bio’s technology to achieve deeper, more interpretable insights into cancer phenotypes through multi-omics integration.
The Future of Cancer Research Is Multi-Omic
AACR 2025 made it clear: the cancer research community is embracing multi-omic strategies to uncover hidden disease drivers and accelerate therapeutic innovation. With the launch of our global phosphoproteomics service, Panome Bio is proud to offer researchers a more complete molecular picture—helping drive discoveries that improve patient outcomes.
Thank you to all who visited us in Chicago—we look forward to continuing the conversation and collaborating on tomorrow’s breakthroughs.